X-Linked Agammaglobulinemia: Infection Frequency and Infection-Related Mortality in the USIDNET Registry

J Clin Immunol. 2022 May;42(4):827-836. doi: 10.1007/s10875-022-01237-1. Epub 2022 Mar 15.

Abstract

X-linked agammaglobulinemia (XLA) is a primary immunodeficiency disorder caused by mutations in the Bruton tyrosine kinase (BTK) gene leading to B lymphocyte deficiency and susceptibility to infection. A potential benefit of earlier diagnosis and treatment initiation on morbidity and mortality in XLA is incompletely understood. In the USIDNET Registry, we describe infection frequency and infection-related mortality in patients with XLA and their relationship to age of diagnosis and treatment initiation. Among the 231 XLA patients enrolled in the Registry, respiratory infections (N = 203, 88%) were the most commonly reported. Among those deceased (N = 20) where cause of death was known (N = 17), mortality was attributed to infection in most (N = 12, 71%). Chronic lung disease, often a consequence of repeated lower respiratory tract infection (LRTI), was also a frequent complication associated with mortality (N = 9, 53%). Age of diagnosis in years was lower for those without LRTI compared to those with (median 1.5 [IQR 0.5-3.3] vs. median 3.0 [IQR 1.0-5.0], p = 0.0026) and among living patients compared to deceased (median 1.8 [IQR 0.5-5.0] vs. median 2.7 [IQR 1.6-6.0], p = 0.04). Age at treatment initiation in years was lower among those without LRTIs compared to those with (median 1.0 [IQR 0.4-2.4] vs. median 2.8 [IQR 1.0-5.4], p = 0.0006). For every year increase in age at start of therapy, the odds of experiencing a LRTI was 1.216 (OR 1.216, 95% CI 1.048-1.411, p = 0.01). Given the expected finding of reduced LRTIs and mortality among those with earlier age at diagnosis, our study findings support inclusion of XLA in newborn screening programs.

Keywords: Immunoglobulin; Infection; Infectious organism; Primary immunodeficiency; USIDNET; X-linked agammaglobulinemia.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Agammaglobulinaemia Tyrosine Kinase / genetics
  • Agammaglobulinemia* / complications
  • Agammaglobulinemia* / diagnosis
  • Agammaglobulinemia* / epidemiology
  • Genetic Diseases, X-Linked* / diagnosis
  • Genetic Diseases, X-Linked* / epidemiology
  • Genetic Diseases, X-Linked* / genetics
  • Humans
  • Infant, Newborn
  • Mutation
  • Registries
  • Respiratory Tract Infections* / epidemiology

Substances

  • Agammaglobulinaemia Tyrosine Kinase

Supplementary concepts

  • Bruton type agammaglobulinemia